Truist analyst Richard Newitter raised the firm’s price target on Boston Scientific (BSX) to $117 from $113 and keeps a Buy rating on the shares. The company delivered an “impressive” revenue and margin outperformance, while its guidance is absorbing the second-half tariff impact, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $120 from $116 at RBC Capital
- Boston Scientific price target lowered to $121 from $122 at Raymond James
- Boston Scientific price target raised to $120 from $115 at Baird
- Boston Scientific’s Strong Q1 2025 Performance and Strategic Positioning Justify Buy Rating
- Boston Scientific’s Strong Q1 2025 Performance and Growth Potential Justifies Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue